TLX

Telix Expands U.S. Development and Manufacturing Infrastructure with Acquisition of IsoTherapeutics

Retrieved on: 
Monday, February 26, 2024
Acquisition, Drug development, GMP, TLX, ASX, Radiochemistry, Reserve Bank

Founded in 2005, IsoTherapeutics is a privately held, commercial-stage company, which provides radiochemistry and bioconjugation development and contract manufacturing services to many companies in the radiopharmaceutical industry, including Telix.

Key Points: 
  • Founded in 2005, IsoTherapeutics is a privately held, commercial-stage company, which provides radiochemistry and bioconjugation development and contract manufacturing services to many companies in the radiopharmaceutical industry, including Telix.
  • In line with Telix’s continued investment in the vertical integration of supply chain, manufacturing and development capabilities, the acquisition is expected to further enhance Telix’s in-house drug development capabilities.
  • A key driver for the acquisition is to enable Telix to bring select aspects of its development programs in-house, with the goal of reducing cost and time to achieve technical milestones.
  • The acquisition will also expand Telix’s U.S. manufacturing footprint with a site that includes a GMP1 clean room and production infrastructure suitable for clinical use.

Telix 2023 Full Year Results: Inaugural Profit Achieved, Strong Revenue Growth Underpins Investment in Late-stage Pipeline

Retrieved on: 
Thursday, February 22, 2024
Marketing, Crown, Growth, U.S. FDA, BLA, Soft-tissue sarcoma, TLX, Ethics, ASX, Commercialization, Webcast, AEDT, Patient, Biologics license application, NDA, Research, Depreciation, Prostate cancer, Pharmaceutical industry

MELBOURNE, Australia, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its results for the financial year ended 31 December 2023.

Key Points: 
  • MELBOURNE, Australia, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its results for the financial year ended 31 December 2023.
  • Dr Christian Behrenbruch, Managing Director and Group CEO commented:
    “This is an excellent result which demonstrates the strength of the Telix business model.
  • Full year revenue for 2024 expected range of US$445M to US$465M ($675M to $705M at current exchange rates), representing an approximate 35-40% increase on 2023.
  • Expected additional investment of 40-50% in R&D (compared with 2023), including both external and internal costs funded by operating cash flow and broadly in line with revenue growth.

Telix Signs Agreement to Acquire QSAM Biosciences and Its Bone Cancer Targeting Platform

Retrieved on: 
Wednesday, February 7, 2024
PRV, Steroid, Prostate cancer, COGS, Contingent value rights, TLX, Palliative care, Osteosarcoma, Patient, Safety, Nephrotoxicity, QSAM, FDA, Appendix, Sarcoma, Food, Term sheet, Brain, Disease, Pain management, Acquisition, Metastasis, Samarium, ODD, Radiopharmaceutical, Aplastic anemia, Glioma, ASX, Priority review, Medical imaging

MELBOURNE, Australia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire QSAM Biosciences, Inc. (U.S. OTC: QSAM) and its lead investigational drug Samarium-153-DOTMP (153Sm-DOTMP).

Key Points: 
  • MELBOURNE, Australia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire QSAM Biosciences, Inc. (U.S. OTC: QSAM) and its lead investigational drug Samarium-153-DOTMP (153Sm-DOTMP).
  • QSAM is a United States (U.S.) based company developing therapeutic radiopharmaceuticals for primary and metastatic bone cancer.
  • Telix believes that 153Sm-DOTMP may benefit patients with metastatic lung and breast cancer, where many patients develop brain and bone metastases, and disease management often focusses on quality-of-life palliative care.
  • Telix will issue ordinary shares to the stockholders of QSAM at closing within its Listing Rule 7.1 placement capacity as consideration for the acquisition.

QSAM Biosciences Signs Definitive Agreement to be Acquired by Telix Pharmaceuticals

Retrieved on: 
Wednesday, February 7, 2024
Regulation D, OTCQB, TLX, Patient, QSAM, Agreement, Acquisition, Metastasis, Samarium, Information, Radiopharmaceutical, ASX, Security (finance)

Austin, TX, Feb. 07, 2024 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM) (“QSAM or the “Company”) has signed a definitive Agreement and Plan of Merger (the “Agreement”) providing for the acquisition of the Company by Telix Pharmaceuticals Limited (ASX: TLX) (“Telix”).

Key Points: 
  • Austin, TX, Feb. 07, 2024 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM) (“QSAM or the “Company”) has signed a definitive Agreement and Plan of Merger (the “Agreement”) providing for the acquisition of the Company by Telix Pharmaceuticals Limited (ASX: TLX) (“Telix”).
  • Prior to closing the merger, QSAM will effect a reverse stock split of its common stock in a ratio between 1:1000 and 1:2000.
  • Each whole share of QSAM common stock outstanding after the reverse split will receive Telix Shares.
  • All QSAM stockholders will receive one CVR for each QSAM common share held prior to the reverse split.

Telix Highlights Presentations at Upcoming ASCO Genitourinary Cancers Symposium (ASCO GU 2024)

Retrieved on: 
Monday, January 22, 2024
ASX, Patient, Prostate cancer, ASCO, Society, Immunotherapy, Renal cell carcinoma, PSMA, GU, Kidney cancer, Prostate, TLX

MELBOURNE, Australia, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces presentations featuring the Company’s theranostic programs at the upcoming American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2024) to be held in San Francisco, CA (US) from 25 – 27 January 2024.

Key Points: 
  • MELBOURNE, Australia, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces presentations featuring the Company’s theranostic programs at the upcoming American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2024) to be held in San Francisco, CA (US) from 25 – 27 January 2024.
  • Dr David N. Cade, Telix Group Chief Medical Officer, said, “We are pleased to present updates on our late-stage therapeutic programs for prostate and kidney cancer at ASCO GU 2024, the leading specialised event for GU cancer care worldwide.
  • “The ProstACT GLOBAL study of TLX591 (177Lu rosopatamab tetraxetan) will be presented, the first Phase III trial to evaluate TLX591, our lead radio-antibody drug conjugate (rADC) therapy candidate in patients with PSMA-positive metastatic castrate-resistant prostate cancer (mCRPC).
  • “Eric Jonasch MD, will present the STARLITE-1 investigator-initiated trial of Telix’s therapy candidate, TLX250 (177Lu girentuximab), in combination with immunotherapy in clear cell renal cell carcinoma, the most common and aggressive form of kidney cancer.

Telix to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Wednesday, January 3, 2024
PST, EST, AEDT, Conference, ASX, TLX

MELBOURNE, Australia, Jan. 03, 2024 (GLOBE NEWSWIRE) --  Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today advises that Dr Christian Behrenbruch, Managing Director and Group CEO, will be presenting at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA (US).

Key Points: 
  • MELBOURNE, Australia, Jan. 03, 2024 (GLOBE NEWSWIRE) --  Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today advises that Dr Christian Behrenbruch, Managing Director and Group CEO, will be presenting at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA (US).
  • The presentation will take place on Tuesday 9 January at 3:00pm PST (6:00pm EST / 10:00am AEDT, 10 January).
  • The webcast will be accessible on demand on the Telix website following the event.
  • To schedule a 1x1 meeting with Telix management, please contact [email protected] .

QSAM Biosciences Signs Term Sheet to be Acquired by Telix Pharmaceuticals; Receives $2 Million Pre-Closing Collaboration and Option Fee

Retrieved on: 
Tuesday, November 14, 2023
Acquisition, OTCQB, TLX, QSAM, FDA, Nuclear pharmacy, ASX, Orphan drug, Contingent value rights, Term sheet, Commercial property, Telix

Upon signing of the Term Sheet, Telix has agreed to pay the Company a US$2 million Pre-Closing Collaboration and Option Fee (the “Collaboration Fee”) to advance the Company’s development efforts based on mutually agreed goals and to provide sixty days of exclusivity pending completion of diligence and execution of a definitive acquisition agreement.

Key Points: 
  • Upon signing of the Term Sheet, Telix has agreed to pay the Company a US$2 million Pre-Closing Collaboration and Option Fee (the “Collaboration Fee”) to advance the Company’s development efforts based on mutually agreed goals and to provide sixty days of exclusivity pending completion of diligence and execution of a definitive acquisition agreement.
  • If the Acquisition does not close, the Collaboration Fee will be converted to Company common stock at a price of 6.70 per share.
  • Dr. C. Richard Piazza, QSAM’s Executive Chairman and co-Founder, stated, “We are thrilled to commence working with Telix by virtue of the Collaboration Fee to advance our technology and pursue a definitive agreement leading to the acquisition of QSAM by Telix.
  • With CycloSam® we plan to leverage Telix’s extensive experience and success in distributing short-life radiopharmaceuticals using a cold kit product from a nuclear pharmacy.

Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer to be Presented at SABCS

Retrieved on: 
Wednesday, November 29, 2023
Research, TLX, Carbonic anhydrase, Breast cancer, IIT, Patient, Triple-negative breast cancer, Congress, ASX, CAIX, Diagnosis, PET, ICO, TNBC, Medical imaging

MELBOURNE, Australia, Nov. 29, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today advises that the completed Phase II OPALESCENCE investigator-initiated trial (IIT) of its carbonic anhydrase IX (CAIX)-targeting positron emission tomography (PET) imaging candidate, TLX250-CDx (89Zr-DFO-girentuximab), in patients with triple-negative breast cancer (TNBC), will be presented at the 2023 San Antonio Breast Cancer Symposium® (SABCS) taking place from December 5-9, 2023.

Key Points: 
  • MELBOURNE, Australia, Nov. 29, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today advises that the completed Phase II OPALESCENCE investigator-initiated trial (IIT) of its carbonic anhydrase IX (CAIX)-targeting positron emission tomography (PET) imaging candidate, TLX250-CDx (89Zr-DFO-girentuximab), in patients with triple-negative breast cancer (TNBC), will be presented at the 2023 San Antonio Breast Cancer Symposium® (SABCS) taking place from December 5-9, 2023.
  • Dr. Caroline Rousseau, Principal Investigator for the OPALESCENCE study (ClinicalTrials.gov ID NCT04758780 ) at the Institut de Cancérologie de l'Ouest (ICO) in St Herblain (France), will deliver top-line results as a poster presentation at 5pm CT on Wednesday December 6.
  • SABCS is the largest and most prestigious scientific gathering on breast cancer research worldwide.
  • Visit http://www.sabcs.org/ for more information on the congress.

Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer to be Presented at SABCS

Retrieved on: 
Wednesday, November 29, 2023
Research, TLX, Carbonic anhydrase, Breast cancer, IIT, Patient, Triple-negative breast cancer, Congress, ASX, CAIX, Diagnosis, PET, ICO, TNBC, Medical imaging

MELBOURNE, Australia, Nov. 29, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today advises that the completed Phase II OPALESCENCE investigator-initiated trial (IIT) of its carbonic anhydrase IX (CAIX)-targeting positron emission tomography (PET) imaging candidate, TLX250-CDx (89Zr-DFO-girentuximab), in patients with triple-negative breast cancer (TNBC), will be presented at the 2023 San Antonio Breast Cancer Symposium® (SABCS) taking place from December 5-9, 2023.

Key Points: 
  • MELBOURNE, Australia, Nov. 29, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today advises that the completed Phase II OPALESCENCE investigator-initiated trial (IIT) of its carbonic anhydrase IX (CAIX)-targeting positron emission tomography (PET) imaging candidate, TLX250-CDx (89Zr-DFO-girentuximab), in patients with triple-negative breast cancer (TNBC), will be presented at the 2023 San Antonio Breast Cancer Symposium® (SABCS) taking place from December 5-9, 2023.
  • Dr. Caroline Rousseau, Principal Investigator for the OPALESCENCE study (ClinicalTrials.gov ID NCT04758780 ) at the Institut de Cancérologie de l'Ouest (ICO) in St Herblain (France), will deliver top-line results as a poster presentation at 5pm CT on Wednesday December 6.
  • SABCS is the largest and most prestigious scientific gathering on breast cancer research worldwide.
  • Visit http://www.sabcs.org/ for more information on the congress.

Telix and Mauna Kea Technologies to Expand Collaboration in Urologic Oncology Surgery

Retrieved on: 
Monday, November 13, 2023
Food and Drug Administration, Radiation, Euronext Growth, Food, Robotics, TLX, Disease, Surgeon, Urology, Mauna Kea Technologies, Patient, Mauna Kea, Medicine, FDA, ASX, Molecular imaging, Iris, Cancer, Partnership, CLE, AI, VWAP, Medical imaging, Security (finance), Telix

Telix's investment in Mauna Kea will further support the development of advanced imaging techniques for minimally invasive (laparoscopic and robotic) surgery, with a specific focus on urologic oncology.

Key Points: 
  • Telix's investment in Mauna Kea will further support the development of advanced imaging techniques for minimally invasive (laparoscopic and robotic) surgery, with a specific focus on urologic oncology.
  • Mauna Kea is a leading medical device company pioneering the development of real-time intraoperative visualisation of cancer tissue during surgery.
  • Mauna Kea's Cellvizio confocal laser endomicroscopy (CLE) in vivo cellular imaging platform has received U.S. Food and Drug Administration (FDA) approval and is CE Marked for a range of applications.
  • Following closing (on 17 November 2023), Telix will own 19.33% of the share capital and 19.01% of the voting rights of Mauna Kea.